We are monitoring the impact of COVID-19 on APAC Thyroid cancer Market Get in touch with us for detailed analysis Know More
Share on

Asia Pacific Thyroid Cancer Market Research Report – Segmented By Treatment, End User and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 2170
Pages: 140

APAC Thyroid Cancer Market Size (2022 to 2027)

As per our report, the size of the Asia Pacific Thyroid Cancer Market was valued at USD 60.37 million in 2022 and is expected to grow at a CAGR of 30.16% to reach USD 225.53 million by 2027.

Thyroid cancer is becoming more common, and there is a greater emphasis on early detection and treatment, which is projected to boost market expansion. Thyroid cancer is a very rare malignancy, yet technologically advanced diagnostic methods have expanded incidence rates in recent years. Factors driving the market include an increase in thyroid cases, an increasing number of government initiatives, and increased investment in research and technological advancements in cancer diagnosis and treatment.

One of the primary factors driving the growth of the Asia Pacific thyroid cancer market is the rise in the number of neuroendocrine tumor cases among the population. It is also accelerated by increased investment in research and development efforts to improve the overall course of diagnosis and treatment of thyroid cancer and expand awareness of therapy and technological improvement. The rise in the number of obese people and the adoption of hazardous lifestyle habits such as junk food and alcohol consumption have a different influence on the thyroid cancer market. Furthermore, an increase in money for treatment from for-profit and nonprofit organizations and an increase in healthcare spending and government assistance have a beneficial impact on the thyroid cancer market in the APAC region.

However, the market's expansion is being stifled by a lack of knowledge regarding the actual causal causes and late detection of the disease. In addition, thyroid cancer market growth is projected to be hampered by the patent expiration of patented drugs, the advent of generic versions of branded drugs, and the high cost of treatment. In the forecast period, the thyroid cancer market is expected to be challenged by a lack of competent specialists and awareness about therapies in this country.

This research report on the Asia Pacific thyroid cancer market has been segmented and sub-segmented into the following categories.

By Treatment:

  • Surgery
  • Iodine Therapy
  • External Therapy
  • Thyroxine treatment
  • Chemotherapy
  • Drugs

By Drug: 

  • Levothyroxine
  • Radioiodine

By End User: 

  • Hospitals
  • Oncology Centres
  • Hospital Pharmacies
  • Retail Pharmacies

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Because of the rising investment in R&D for the development of new pharmaceuticals and techniques for thyroid cancer therapy in the area, the market in the Asia Pacific is expected to grow at the fastest CAGR over the forecast period. The market in the Asia Pacific is expected to grow at the quickest rate throughout the forecast period because of factors such as rising thyroid cancer prevalence, higher consumer awareness, improved healthcare infrastructure, and increased disposable income. During the projection period, the market for thyroid cancer diagnostics in growing countries such as China, India, and South Korea is likely to grow rapidly. Thyroid cancer diagnostics may experience substantial expansion in Asia-Pacific as well, given the region's rapid development and the government's efforts to raise awareness about the condition. This market is becoming increasingly competitive as significant companies focus on strategic efforts such as product launches and development, mergers and acquisitions, licensing alliances, and co-development deals. Furthermore, numerous healthcare companies invest in this region, and the regional population's disposable income is rising. As a result of all factors, the thyroid cancer market in Asia-Pacific is expected to increase in the next few years.

KEY MARKET PLAYERS:

Noteworthy players dominating the APAC Thyroid Cancer Market profiled in this report are Baxter International Inc., Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Bristol Myers co, Abbott laboratories, Teva parenteral medicines Inc., App pharmaceuticals LLC, and Jerome Stevens Pharmaceuticals Inc.

1.Introduction                                                                  

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                          

                1.4 General Study Assumptions                                                

2. Research Methodology                                                                           

                2.1 Introduction                                                               

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                           

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                      

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

3. Overview                                                                       

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 Epidemology                                                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                    

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                                              

5. Market Segmentation                                                                              

                5.1 Treatment                                                  

                                5.1.1 Introduction                                           

                                5.1.2 Surgery                                     

                                5.1.3 Iodine Theraphy                                   

                                5.1.4 External radiotherapy                                        

                                5.1.5 Thyroxine treatment                                          

                                5.1.6  chemotherapy                                     

                                5.1.7 Drugs                                         

                                5.1.8  Y-o-Y Growth Analysis, By Treatment                                         

                                5.1.9  Market Attractiveness Analysis, By Treatment                                       

                                5.1.10 Market Share Analysis, By Treatment                                       

                5.2 End User      

                                5.2.1 Introduction                                           

                                5.2.2 Hospital                                    

                                5.2.3 Oncology centers                                 

                                5.2.4 Hospital Pharmacies                                            

                                5.2.5 Retail Pharmacies                                 

                                5.2.6 Y-o-Y Growth Analysis, By End User                                             

                                5.2.7 Market Attractiveness Analysis, By End User                                           

                                5.2.8 Market Share Analysis, By End User                                             

6. Geographical Analysis                                                                              

                6.1 Introduction                                                               

                                6.1.1 Regional Trends                                    

                                6.1.2 Impact Analysis                                     

                                6.1.3 Y-o-Y Growth Analysis                                        

                                                6.1.3.1 By Geographical Area                     

                                                6.1.3.2 By Treatment                     

                                                6.1.3.3 By End User                        

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area                     

                                                6.1.4.2 By Treatment                     

                                                6.1.4.3 By End User                        

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area                     

                                                6.1.5.2 By Treatment                     

                                                6.1.5.3 By End User                        

                6.2 China                                                             

                6.3 India                                                              

                6.4 Japan                                                            

                6.5 South Korea                                                               

                6.6 Australia                                                      

7.Strategic Analysis                                                                        

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                       

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                                              

                                7.2.5 Competitive Rivalry within the Industry                                     

8.Market Leaders' Analysis                                                                         

                8.1 Baxter International Inc                                                        

                                8.1.1 Overview                                 

                                8.1.2 Product Analysis                                   

                                8.1.3 Financial analysis                                  

                                8.1.4 Recent Developments                                       

                                8.1.5 SWOT analysis                                       

                                8.1.6 Analyst View                                          

                8.2 Mylan pharmaceuticals Inc                                                  

                8.3 Alara Pharmaceutical Corporation                                                    

                8.4  Bristol Myers co                                                       

                8.5  Abbott laboratories                                                               

                8.6 Teva parenteral medicines Inc                                                           

                8.7 App pharmaceuticals llc                                                         

                8.8  Jerome Stevens Pharmaceuticals Inc                                                             

9.Competitive Landscape                                                                            

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                         

                9.4 New Product Launches                                                         

10.Market Outlook and Investment Opportunities                                                                          

Appendix                                                                           

                a) List of Tables                                                

                b) List of Figures                                                              

  1. Asia Pacific Thyroid Cancer Market, By Treatment, From 2022 - 2027 (USD Million)
  2. Asia Pacific Surgery Market, By Region, From 2022 - 2027 (USD Million)
  3. Asia Pacific Iodine Theraphy Market, By Region, From 2022 - 2027 (USD Million)
  4. Asia Pacific External radiotherapy Market, By Region, From 2022 - 2027 (USD Million)
  5. Asia Pacific Thyroxine treatment Market, By Region, From 2022 - 2027 (USD Million)
  6. Asia Pacific chemotherapy Market, By Region, From 2022 - 2027 (USD Million)
  7. Asia Pacific Drugs Market, By Region, From 2022 - 2027 (USD Million)
  8. Asia Pacific Thyroid Cancer Market, By End User, From 2022 - 2027 (USD Million)
  9. Asia Pacific Hospitals Market, By Region, From 2022 - 2027 (USD Million)
  10. Asia Pacific Oncology Centers Market, By Region, From 2022 - 2027 (USD Million)
  11. Asia Pacific Hospital Pharmacies Market, By Region, From 2022 - 2027 (USD Million)
  12. Asia Pacific Retail Pharmacies Market, By Region, From 2022 - 2027 (USD Million)
  13. Japan Thyroid Cancer Market, By Treatment, From 2022 - 2027 (USD Million)
  14. Japan Thyroid Cancer Market, By End User, From 2022 - 2027 (USD Million)
  15. China Thyroid Cancer Market, By Treatment, From 2022 - 2027 (USD Million)
  16. China Thyroid Cancer Market, By End User, From 2022 - 2027 (USD Million)
  17. India Thyroid Cancer Market, By Treatment, From 2022 - 2027 (USD Million)
  18. India Thyroid Cancer Market, By End User, From 2022 - 2027 (USD Million)
  19. Australia Thyroid Cancer Market, By Treatment, From 2022 - 2027 (USD Million)
  20. Australia Thyroid Cancer Market, By End User, From 2022 - 2027 (USD Million)
  21. South Korea Thyroid Cancer Market, By Treatment, From 2022 - 2027 (USD Million)
  22. South Korea Thyroid Cancer Market, By End User, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample